Novadaq's SPY tech labelling:
This article was originally published in Clinica
The US FDA has given Novadaq Technologies 510(k) clearance to revise the labelling of its SPY intra-operative imaging system, a fluorescence-based guided technology that enables cardiac surgeons to visually assess coronary vasculature and bypass graft functionality during open-heart bypass surgery. The revision allows direct injection of the imaging agent to the vessels in the region of interest, giving the surgeon greater flexibility without posing any additional risk to the patient, said the Toronto, Canada firm. In addition, the company has also begun two additional clinical trials in different therapeutic applications for SPY - cerebral angiography during neurosurgery and the evaluation of access points for renal failure patients undergoing haemodialysis. Applying the imaging platform to different therapeutic areas, with no significant investment in technology, demonstrates the potential to expand the market opportunity for Novadaq, the firm said.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.